Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1673 1693
This examiner grants 66% of resolved cases
Layla D Berry is an examiner in Tech Center 1600 and Art Unit 1623 with 1456 resolved cases. Her allowance rate is 66.0 percent, and the median days to allowance is 1016. These metrics provide a statistical basis for observations within the 1600 tech center. The 1016-day median is a benchmark for the duration of the 1456 cases she has handled.
The interview lift of 9.0 percent is a factor compared to the 66.0 percent allowance rate. This suggests that interviews provide a modest improvement in the probability of a grant. For the 1456 cases resolved, the 1016-day median pendency highlights the importance of a steady prosecution strategy. The 9.0 percent lift indicates that direct communication can help resolve some issues, though the baseline allowance rate remains a primary consideration. Practitioners should use the 1016-day median to set expectations for their clients.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18832718 | NOVEL USE | Non-Final OA | DSM IP Assets B.V. |
| 18655876 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | Final Rejection | Gilead Sciences, Inc. |
| 18838712 | USE OF RHAMNOLIPID(S) FOR PREVENTING THE COLOURATION OF CUTANEOUS BLACKHEADS | Non-Final OA | L'OREAL |
| 18698396 | PROCESS FOR MAKING MELT PROCESSABLE CELLULOSE ESTER COMPOSITIONS COMPRISING ALKALINE FILLER | Non-Final OA | Eastman Chemical Company |
| 18597314 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | Final Rejection | Boehringer Ingelheim International GmbH |
| 18251358 | COMPOSITIONS COMPRISING METHYL CYCLODEXTRINS FOR THE TREATMENT AND/OR PREVENTION OF HEPATIC STEATOSIS | Non-Final OA | ROQUETTE FRERES |
| 18835370 | PHENOXAZINE DERIVATIVE AND DRUG DELIVERY SYSTEM FORMULATION USING SAME | Non-Final OA | Osaka University |
| 17620541 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | Non-Final OA | CELGENE CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy